{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:08Z","timestamp":1790957528424,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T00:00:00Z","timestamp":1671926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T00:00:00Z","timestamp":1671926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s13300-022-01359-0","type":"journal-article","created":{"date-parts":[[2022,12,25]],"date-time":"2022-12-25T06:02:10Z","timestamp":1671948130000},"page":"415-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-5187","authenticated-orcid":false,"given":"Samit","family":"Ghosal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binayak","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,25]]},"reference":[{"issue":"12","key":"1359_CR1","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.2215\/CJN.11491116","volume":"12","author":"RZ Alicic","year":"2017","unstructured":"Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032\u201345.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3390\/kidneydial2030038","volume":"2","author":"E Hoogeveen","year":"2022","unstructured":"Hoogeveen E. The epidemiology of diabetic kidney disease. Kidney Dial. 2022;2:433\u201342. https:\/\/doi.org\/10.3390\/kidneydial2030038.","journal-title":"Kidney Dial"},{"issue":"4","key":"1359_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.3904\/kjim.2016.219","volume":"32","author":"MK Kim","year":"2017","unstructured":"Kim MK. Treatment of diabetic kidney disease: current and future targets. Korean J Intern Med. 2017;32(4):622\u201330.","journal-title":"Korean J Intern Med"},{"issue":"6","key":"1359_CR4","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/nep.13860","volume":"26","author":"M Sugahara","year":"2021","unstructured":"Sugahara M, Pak WLW, Tanaka T, Tang SCW, Nangaku M. Update on diagnosis, pathophysiology, and management of diabetic kidney disease. Nephrology (Carlton). 2021;26(6):491\u2013500.","journal-title":"Nephrology (Carlton)"},{"key":"1359_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/697010","author":"S Toth-Manikowski","year":"2015","unstructured":"Toth-Manikowski S, Atta M. Diabetic kidney disease: pathophysiology and therapeutic targets. J Diabetes Res. 2015. https:\/\/doi.org\/10.1155\/2015\/697010.","journal-title":"J Diabetes Res"},{"issue":"23","key":"1359_CR6","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.3390\/ijms20235831","volume":"20","author":"V Nin\u010devi\u0107","year":"2019","unstructured":"Nin\u010devi\u0107 V, Omanovi\u0107 Kolari\u0107 T, Rogulji\u0107 H, Kizivat T, Smoli\u0107 M, Bili\u0107 \u0106I. Renal benefits of SGLT 2 inhibitors and GLP-1 receptor agonists: evidence supporting a paradigm shift in the medical management of type 2 diabetes. Int J Mol Sci. 2019;20(23):5831.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1359_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.23876\/j.krcp.2018.37.3.183","volume":"37","author":"DR Cha","year":"2018","unstructured":"Cha DR. Mineralocorticoid receptor blockade for renoprotection. Kidney Res Clin Pract. 2018;37(3):183\u20134.","journal-title":"Kidney Res Clin Pract"},{"key":"1359_CR8","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;2021:372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"1359_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204233?articleTools=true","author":"The EMPA-KIDNEY Collaborative Group","year":"2022","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2204233?articleTools=true.","journal-title":"New Engl J Med"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/nejmoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375:323\u201334. https:\/\/doi.org\/10.1056\/nejmoa1515920.","journal-title":"N Engl J Med"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385:1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Fet al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387:1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286.","journal-title":"N Engl J Med"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"9","key":"1359_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","volume":"6","author":"V Perkovic","year":"2018","unstructured":"Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691\u2013704.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"key":"1359_CR19","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383:2219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2025845.","journal-title":"N Engl J Med"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385:2252\u201363.","journal-title":"N Engl J Med"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/nejmoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339. https:\/\/doi.org\/10.1056\/nejmoa1612917.","journal-title":"N Engl J Med"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021;385:896\u2013907. https:\/\/doi.org\/10.1056\/NEJMoa2108269.","journal-title":"N Engl J Med"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/nejmoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322. https:\/\/doi.org\/10.1056\/nejmoa1603827.","journal-title":"N Engl J Med"},{"issue":"10193","key":"1359_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3.","journal-title":"Lancet"},{"key":"1359_CR25","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/nejmoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344. https:\/\/doi.org\/10.1056\/nejmoa1607141.","journal-title":"N Engl J Med"},{"key":"1359_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000506634","volume":"6","author":"Y Chen","year":"2020","unstructured":"Chen Y, Lee K, Ni Z, He JC. Diabetic kidney disease: challenges, advances, and opportunities. Kidney Dis. 2020;6:215\u201325. https:\/\/doi.org\/10.1159\/000506634.","journal-title":"Kidney Dis"},{"issue":"4","key":"1359_CR27","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","volume":"98","author":"I de Boer","year":"2020","unstructured":"de Boer I, Caramori LM, Chan J, et al. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(4):S1\u2013115. https:\/\/doi.org\/10.1016\/j.kint.2020.06.019.","journal-title":"Kidney Int"},{"key":"1359_CR28","doi-asserted-by":"publisher","unstructured":"Kawai Y, Uneda K, Yamada T, et al. Comparison of effects of SGLT-2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus patients with\/without albuminuria: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2022;183:109146. https:\/\/doi.org\/10.1016\/j.diabres.2021.109146.","DOI":"10.1016\/j.diabres.2021.109146"},{"key":"1359_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751496","volume":"12","author":"LM Zhao","year":"2022","unstructured":"Zhao LM, Zhan ZL, Ning J, Qiu M. Network meta-analysis on the effects of SGLT2 inhibitors versus finerenone on cardiorenal outcomes in patients with type 2 diabetes and chronic kidney disease. Front Pharmacol. 2022;12: 751496.","journal-title":"Front Pharmacol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-022-01359-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-022-01359-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T20:52:24Z","timestamp":1677012744000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-022-01359-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,25]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s13300-022-01359-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,25]]},"assertion":[{"value":"17 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}